Focus: Lantheus is a public-stage specialty biotech focused on small-molecule radiopharmaceuticals and imaging agents for oncology, cardiovascular, nephrology, metabolic, and respiratory diseases. The company operates in the high-margin medical imaging market with a diversified portfolio of legacy and emerging diagnostic agents.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Lantheus Medical Imaging to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Lantheus Medical Imaging's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Established radiopharmaceutical for pulmonary ventilation imaging; patent exclusivity eroding with generic competition risk.
Help build intelligence for Lantheus Medical Imaging
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Cornerstone ultrasound contrast agent with extended LOE runway to 2037; multiple Phase 2–4 indications in expansion (renal cell carcinoma, compartment syndrome, cardiac disease).
Legacy radiopharmaceutical for malignancy and infection localization; approaching LOE with patent cliff risk.
Historical standard for ischemia and infarction detection via stress testing; losing exclusivity with transition risk to newer PET agents.
Pre-launch reformulation/rebranding of xenon xe-133; potential near-term catalyst if approved, though parent compound faces LOE cliff.
Albumin-binding MRI contrast agent for vascular imaging; patent exclusivity eroding, with Phase 4 trial activity suggesting clinical validation efforts.
Core product equivalent to DEFINITY RT; extended exclusivity to 2037 and robust Phase 2–4 pipeline expansion across cardiac, renal, and vascular indications.
6 discontinued, 1 duplicate formulations not shown
Radiopharmaceutical Theranostics Market Insights Highlight Segment Expansion And Market Leadership - openPR.com
Radiopharmaceutical Theranostics Market Insights Highlight Segment Expansion And Market Leadership openPR.com
Core Points in the Radiopharmaceuticals for Nuclear Medicine Market|QYResearch - note
Core Points in the Radiopharmaceuticals for Nuclear Medicine Market|QYResearch note
Curium inks definitive deal to acquire radiopharma rival Lantheus for up to $8B - Radiology Business
Curium inks definitive deal to acquire radiopharma rival Lantheus for up to $8B Radiology Business
8-K Filing: Lantheus Holdings, Inc. (LNTH) (CIK 0001521036) — EX-10.2
EX-10.2
U.S. Nuclear Medicine Market Size, Share, Trends, Growth 2032 - Fortune Business Insights
U.S. Nuclear Medicine Market Size, Share, Trends, Growth 2032 Fortune Business Insights
Lantheus Medical Imaging Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Lantheus Medical Imaging Number of Employees 2026 | Employee Count & Headcount Data Revelio Labs
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo